[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kymera Therapeutics insider transactions by CEO and director Nello Mainolfi on 09/16/2025: The filing shows the exercise of a fully vested stock option with a $2.08 exercise price that converted into 30,000 shares, and an offsetting sale of 30,000 shares at $49. Following these transactions the reporting person beneficially owned 660,482 shares.

The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted September 6, 2024, and the derivative shares underlying the option are fully vested and exercisable with an expiration date of November 13, 2029.

Positive

• Exercise of fully vested options at a $2.08 price converted compensation into shares, realizing substantial intrinsic value.
• Transactions were executed under a Rule 10b5-1 trading plan dated September 6, 2024, indicating pre-planned, compliant trading procedures.

Negative

• Beneficial ownership decreased by 30,000 shares, from 690,482 to 660,482, reflecting a sale that reduced the reporting person's stake.

Insights

Financial Analyst

TL;DR: CEO exercised vested options and sold the same number of shares under a pre-set 10b5-1 plan; overall beneficial holdings decreased modestly.

The transaction structure—exercise at $2.08 followed by an immediate sale at $49—realizes intrinsic value from long-dated, fully vested options and converts equity-based compensation into cash. The use of a Rule 10b5-1 plan reduces insider trading timing risk and signals pre-planned liquidity rather than opportunistic trading. The net beneficial ownership declined by 30,000 shares to 660,482, a small percentage change relative to total holdings disclosed.

Corporate Governance Expert

TL;DR: The filing documents compliant, pre-arranged insider transactions with vested option exercise; governance controls (10b5-1) were in place.

From a governance perspective, the adoption and use of a 10b5-1 plan provides procedural safeguards against selective disclosure or suspicion of insider timing. The reporting includes required disclosures: exercise price, sale price, plan adoption date, and confirmation that underlying options were fully vested. No departures from standard compliance or unusual acceleration language are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		M(1)		30,000	A	$2.08	690,482	D
Common Stock	09/16/2025		S(1)		30,000	D	$49	660,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	09/16/2025		M(1)			30,000	(2)	11/13/2029	Common Stock	30,000	$0	435,559	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Nello Mainolfi report on Form 4 for KYMR?

The filing reports the exercise of a stock option for 30,000 shares at a $2.08 exercise price and the sale of 30,000 shares at $49 on 09/16/2025.

How many KYMR shares does the reporting person own after these trades?

After the reported transactions the reporting person beneficially owned 660,482 shares.

Were these trades part of a scheduled trading plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024.

Are the options involved in the transaction vested and exercisable?

Yes. The filing states the shares underlying the stock option are fully vested and exercisable, with an expiration of November 13, 2029.

What prices were involved in the transactions reported on Form 4?

The option was exercised at $2.08 per share and the subsequent sale price reported was $49 per share.